244 related articles for article (PubMed ID: 26161668)
1. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.
Jin Y; Elalaf H; Watanabe M; Tamaki S; Hineno S; Matsunaga K; Woltjen K; Kobayashi Y; Nagata S; Ikeya M; Kato T; Okamoto T; Matsuda S; Toguchida J
PLoS One; 2015; 10(7):e0131998. PubMed ID: 26161668
[TBL] [Abstract][Full Text] [Related]
2. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
[TBL] [Abstract][Full Text] [Related]
3. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
4. Mutant IDH is sufficient to initiate enchondromatosis in mice.
Hirata M; Sasaki M; Cairns RA; Inoue S; Puviindran V; Li WY; Snow BE; Jones LD; Wei Q; Sato S; Tang YJ; Nadesan P; Rockel J; Whetstone H; Poon R; Weng A; Gross S; Straley K; Gliser C; Xu Y; Wunder J; Mak TW; Alman BA
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2829-34. PubMed ID: 25730874
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
6. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
[TBL] [Abstract][Full Text] [Related]
7. The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation.
Liu L; Hu K; Feng J; Wang H; Fu S; Wang B; Wang L; Xu Y; Yu X; Huang H
BMC Cancer; 2021 Jan; 21(1):36. PubMed ID: 33413208
[TBL] [Abstract][Full Text] [Related]
8. Induction of sarcomas by mutant IDH2.
Lu C; Venneti S; Akalin A; Fang F; Ward PS; Dematteo RG; Intlekofer AM; Chen C; Ye J; Hameed M; Nafa K; Agaram NP; Cross JR; Khanin R; Mason CE; Healey JH; Lowe SW; Schwartz GK; Melnick A; Thompson CB
Genes Dev; 2013 Sep; 27(18):1986-98. PubMed ID: 24065766
[TBL] [Abstract][Full Text] [Related]
9. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.
Pansuriya TC; van Eijk R; d'Adamo P; van Ruler MA; Kuijjer ML; Oosting J; Cleton-Jansen AM; van Oosterwijk JG; Verbeke SL; Meijer D; van Wezel T; Nord KH; Sangiorgi L; Toker B; Liegl-Atzwanger B; San-Julian M; Sciot R; Limaye N; Kindblom LG; Daugaard S; Godfraind C; Boon LM; Vikkula M; Kurek KC; Szuhai K; French PJ; Bovée JV
Nat Genet; 2011 Nov; 43(12):1256-61. PubMed ID: 22057234
[TBL] [Abstract][Full Text] [Related]
10. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
11. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.
Suijker J; Baelde HJ; Roelofs H; Cleton-Jansen AM; Bovée JV
Oncotarget; 2015 Jun; 6(17):14832-42. PubMed ID: 26046462
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
13. IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.
Saiji E; Pause FG; Lascombes P; Cerato Biderbost C; Marq NL; Berczy M; Merlini L; Rougemont AL
Virchows Arch; 2019 Nov; 475(5):625-636. PubMed ID: 31240473
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
[TBL] [Abstract][Full Text] [Related]
15. IDH1 R132C and ERC2 L309I Mutations Contribute to the Development of Maffucci's Syndrome.
Cheng P; Chen K; Zhang S; Mu KT; Liang S; Zhang Y
Front Endocrinol (Lausanne); 2021; 12():763349. PubMed ID: 34790172
[TBL] [Abstract][Full Text] [Related]
16. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
[TBL] [Abstract][Full Text] [Related]
17. Maffucci syndrome complicated by three different central nervous system tumors sharing an IDH1 R132C mutation: case report.
Nejo T; Tanaka S; Ikemura M; Nomura M; Takayanagi S; Shin M; Ushiku T; Shibahara J; Saito N; Mukasa A
J Neurosurg; 2018 Dec; 131(6):1829-1834. PubMed ID: 30579273
[TBL] [Abstract][Full Text] [Related]
18. Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report.
Lv H; Jiang H; Zhang M; Luo H; Hong Z; Yang H; Xu W; Shen B; Zhang W; Qiu H; Zhu R
World J Surg Oncol; 2022 Jun; 20(1):218. PubMed ID: 35765075
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Kato Kaneko M; Liu X; Oki H; Ogasawara S; Nakamura T; Saidoh N; Tsujimoto Y; Matsuyama Y; Uruno A; Sugawara M; Tsuchiya T; Yamakawa M; Yamamoto M; Takagi M; Kato Y
Cancer Sci; 2014 Jun; 105(6):744-8. PubMed ID: 24898068
[TBL] [Abstract][Full Text] [Related]
20.
Cleven AHG; Suijker J; Agrogiannis G; Briaire-de Bruijn IH; Frizzell N; Hoekstra AS; Wijers-Koster PM; Cleton-Jansen AM; Bovée JVMG
Clin Sarcoma Res; 2017; 7():8. PubMed ID: 28484589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
